TLR-Mediated Production of Reactive Oxygen Species and Tumor Necrosis Factor Alpha by Human Peripheral Blood Neutrophils


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription Access

Abstract

This paper presents the study on TLR-mediated production of reactive oxygen species and tumor necrosis factor alpha by peripheral blood neutrophils in healthy donors stimulated with zymosan (TLR2/6 ligand), peptidoglycan (TLR2/1 ligand), and lipopolysaccharide (TLR4 ligand). Luminol- and lucigen-independent chemiluminescence was used to detect the production of reactive oxygen species. The concentration of tumor necrosis factor alpha was measured by enzyme immunoassay. The plots of dependence of the light sums of luminol- and lucigenin-dependent chemiluminescence on the concentration of each ligand were shaped as saturation curves. The comparison of the light sums of lucigenin-dependent chemiluminescence (the production of superoxide anion radical) and luminol-dependent chemiluminescence (the total production of reactive oxygen species) showed that the contribution of NADPH oxidase to the total TLR-mediated production of oxidants can reach 40–50%. Stimulation indices were calculated to compare the ability of TLR ligands to stimulate the production of reactive oxygen species and tumor necrosis factor alpha by neutrophils. It has been established that the activation of neutrophils with zymosan leads to higher (more than 8-fold) production of reactive oxygen species rather than production of tumor necrosis factor alpha. Unlike zymosan, lipopolysaccharide stimulated the production of tumor necrosis factor alpha to a greater extent (by more than 2 times) than the production of reactive oxygen species. Peptidoglycan takes an intermediate position between these ligands. Thus, the production of effector molecules (reactive oxygen species and tumor necrosis factor alpha) by human peripheral blood neutrophils depends on the nature of the TRL ligand.

About the authors

Yu. O. Teselkin

Pirogov Russian National Research Medical University

Author for correspondence.
Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

M. V. Khoreva

Pirogov Russian National Research Medical University

Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

A. V. Veselova

Pirogov Russian National Research Medical University

Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

I. V. Babenkova

Pirogov Russian National Research Medical University

Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

A. N. Osipov

Pirogov Russian National Research Medical University

Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

L. V. Gankovskaya

Pirogov Russian National Research Medical University

Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

Yu. A. Vladimirov

Pirogov Russian National Research Medical University

Email: teselkin-box@mail.ru
Russian Federation, Moscow, 117997

Supplementary files

Supplementary Files
Action
1. JATS XML

Copyright (c) 2018 Pleiades Publishing, Inc.